 Association disease-free survival percent ideal dose adjuvant breast chemotherapy relationship percent ideal dose disease-free survival Stage II III patients breast adjuvant chemotherapy trial consisting cyclophosphamide methotrexate CMF previous work results dose-response relationship improved disease-free survival patients doses adjuvant chemotherapy major criticism analysis bias bias patients therapy months dose-response relationship causality apparent differences disease-free survival dose groups recurrences first years patients doses chemotherapy